GL1X · GenesisL1 explorer

Research workbench

Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor

Analyse Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5LMB
Type
protein
Length
527 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein kinase syk
EC
2.7.10.2
UniProt
P43405
Ligands
6ZF
Pockets
5 · best druggability 0.68

Structure

x-ray diffraction · 2 distinct chains · 40% helix, 24% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein kinase syk (EC 2.7.10.2)protein26540% helix, 23% strandP43405
BTyrosine-protein kinase syk (EC 2.7.10.2)protein26239% helix, 25% strandP43405

Ligands and binding sites

  • 6ZF · 7-[6-(dimethylamino)pyridin-3-yl]-~{N}-[[(3~{S})-piperidin-3-yl]methyl]pyrido[3,4-b]pyrazin-5-amine · ligand · 2 copies · chains A, B
  • GOL · Glycerol · additive · 7 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15660.680.78636ZF, GOL
22830.620.80366ZF
32290.540.7733GOL
4980.340.7319empty
5600.300.7516empty

Interfaces

1 interface between chains.

  • A–B · 580 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 modified (phosphorylation).

Compared structures

  • 5LMB · Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.